205 related articles for article (PubMed ID: 9916332)
21. Postmarketing surveillance and other epidemiologic uses of drug prescription data in the United States.
Strom BL
Ann Ist Super Sanita; 1991; 27(2):235-7. PubMed ID: 1755576
[TBL] [Abstract][Full Text] [Related]
22. [Joint program of pharmacovigilance in Quebec: comparison with France, Aquitaine and the Basque region].
Biron P; Balency D
Therapie; 1996; 51(5):578-81. PubMed ID: 9138400
[TBL] [Abstract][Full Text] [Related]
23. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
24. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.
Koh Y; Yap CW; Li SC
Int J Med Inform; 2008 Jun; 77(6):421-30. PubMed ID: 17921048
[TBL] [Abstract][Full Text] [Related]
25. [Can the sub-notification of drug adverse effects by capture/recapture method be evaluated?].
Jonville-Béra AP; Autret E
Therapie; 1996; 51(2):169-75. PubMed ID: 8763052
[TBL] [Abstract][Full Text] [Related]
26. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
[TBL] [Abstract][Full Text] [Related]
27. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
28. Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai.
Du W; Levine M; Wang L; Zhang Y; Yi C; Wang H; Wang X; Xie H; Xu J; Jin H; Wang T; Huang G; Wu Y
Can J Clin Pharmacol; 2007; 14(1):e40-4. PubMed ID: 17237524
[TBL] [Abstract][Full Text] [Related]
29. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
Goldman SA
Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
[No Abstract] [Full Text] [Related]
30. Safety monitoring of new anti-malarials in immediate post-marketing phase.
Edwards IR
Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system.
Ortega A; Aguinagalde A; Lacasa C; Aquerreta I; Fernández-Benítez M; Fernández LM
Ann Pharmacother; 2008 Oct; 42(10):1491-6. PubMed ID: 18780808
[TBL] [Abstract][Full Text] [Related]
32. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
33. A new method for assessing drug causation provided agreement with experts' judgment.
Arimone Y; Bégaud B; Miremont-Salamé G; Fourrier-Réglat A; Molimard M; Moore N; Haramburu F
J Clin Epidemiol; 2006 Mar; 59(3):308-14. PubMed ID: 16488362
[TBL] [Abstract][Full Text] [Related]
34. [French pharmacovigilance database system: examples of utilisation].
Moore N; Noblet C; Kreft-Jais C; Lagier G; Ollagnier M; Imbs JL
Therapie; 1995; 50(6):557-62. PubMed ID: 8745956
[TBL] [Abstract][Full Text] [Related]
35. [Events and adverse reactions in biovigilance: Descriptive analysis of French national data following a four-year practical experience].
Martinière K; Lucas S; Zorzi P
Transfus Clin Biol; 2008 Sep; 15(4):179-89. PubMed ID: 18538607
[TBL] [Abstract][Full Text] [Related]
36. Propensity score methods in drug safety studies: practice, strengths and limitations.
Wang J; Donnan PT
Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
[No Abstract] [Full Text] [Related]
37. [Users of a regional center of pharmacovigilance].
Haramburu F; Abraham E; Bégaud B
Therapie; 1993; 48(5):475-7. PubMed ID: 8146828
[TBL] [Abstract][Full Text] [Related]
38. European commission consultation on pharmacovigilance.
Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
[No Abstract] [Full Text] [Related]
39. OPPIDUM surveillance program: 20 years of information on drug abuse in France.
Frauger E; Moracchini C; Le Boisselier R; Braunstein D; Thirion X; Micallef J;
Fundam Clin Pharmacol; 2013 Dec; 27(6):672-82. PubMed ID: 23510229
[TBL] [Abstract][Full Text] [Related]
40. Adverse drug reactions and reporting.
Witte R
Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
